Will Congress Throw Out a Tool to Fight Money Laundering and Corruption?

Key Takeaways

• House Financial Services Committee advanced CTA repeal bill 26‑25 vote
• CTA forces firms to disclose owners over 25% to FinCEN for investigations
• Eleventh Circuit affirmed CTA’s constitutionality; Supreme Court review still pending
• Repeal would re‑enable anonymous shell companies, boosting criminal financing
• Annual compliance cost per small business is under $100, not $1 billion

Pulse Analysis

The Corporate Transparency Act was a rare bipartisan achievement, closing a long‑standing gap that let anyone form a U.S. corporation without revealing its true owners. By requiring beneficial‑ownership reporting to FinCEN, the CTA gave law‑enforcement agencies a critical data source to trace illicit cash flows linked to drug cartels, human‑trafficking rings, and foreign kleptocrats. The move aligned the United States with more than 100 jurisdictions that have adopted similar registries, reinforcing its commitments under the Financial Action Task Force.

Despite the law’s modest compliance burden—estimated at under $100 per small business annually—political opponents have framed the CTA as a costly overreach. A Heritage Foundation estimate of $1 billion in yearly costs was based on speculative assumptions and has been repeatedly debunked. The Eleventh Circuit Court of Appeals reaffirmed the act’s constitutionality under the Commerce Clause, and a pending Supreme Court petition remains the only legal avenue for challengers. Meanwhile, the Trump administration’s suspension of domestic enforcement and its plan to delete existing beneficial‑ownership data have raised concerns about the rule’s practical effectiveness.

If Congress repeals the CTA, the United States would revert to a pre‑2021 regime where shell companies can operate anonymously, eroding a key investigative tool for federal agencies. This rollback would not only hamper efforts to combat money laundering, terrorism financing, and transnational crime, but also risk isolating the U.S. from international AML standards. Policymakers may need to consider targeted refinements rather than a full repeal to preserve the law’s core benefits while addressing legitimate cost concerns.